Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The clot cases conference: a proposed model to enhance multidisciplinary thrombosis care.

Journal of thrombosis and thrombolysis·2025

Same author

The FDA's proposed rule on laboratory-developed tests: what happens next?

Laboratory medicine·2024

Same author

Automation of a Factor XIII Activity Assay Utilizing a Plasma Blank Measurement.

Methods in molecular biology (Clifton, N.J.)·2023

Same author

Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT.

Blood·2022

Same author

Safety of BNT162b2 mRNA vaccine booster in the setting of Ad26.COV2.S-associated VITT.

Blood advances·2022

Same author

Establishing reference intervals for von Willebrand factor multimers.

Journal of medical biochemistry·2022

Same journal

EIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion-Dependent Thalassemia.

American journal of hematology·2026

Same journal

Subtotal Versus Total Splenectomy in Children With Sickle Cell Disease: Clinical Outcomes and Splenic Function Assessed by Pocked Red Blood Cell Count.

American journal of hematology·2026

Same journal

High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1.

American journal of hematology·2026

Same journal

Peripheral Blood Lymphocytosis Reflecting an Underlying Thymoma.

American journal of hematology·2026

Same journal

Undetectable Hydroxyurea Levels in the Majority of Sickle Cell Disease Patients, Especially in Young Children.

American journal of hematology·2026

Same journal

Myelodysplastic Syndromes: 2026 Update on Diagnosis, Risk-Stratification and Management.

American journal of hematology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 1, 2026

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

Chromogenic factor VIII activity assay.

Karen A Moser¹, Dorothy M Adcock Funk

¹Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, Colorado.

American Journal of Hematology

|March 29, 2014

Summary

This summary is machine-generated.

This review compares three Factor VIII (FVIII) activity assays: one-stage clotting, two-stage clotting, and chromogenic. It discusses their methodologies, interferences, and when chromogenic assays may be preferred for hemophilia A diagnosis.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Related Experiment Videos

Last Updated: May 1, 2026

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

Area of Science:

Clinical Laboratory Science
Hematology
Coagulation Diagnostics

Background:

Factor VIII (FVIII) activity is crucial for diagnosing and managing hemophilia A.
Accurate FVIII measurement relies on validated laboratory methodologies.
Clinical laboratory assays for FVIII include one-stage clotting, two-stage clotting, and chromogenic methods.

Purpose of the Study:

To review and compare the three primary methodologies for measuring Factor VIII (FVIII) activity.
To discuss the advantages, disadvantages, and interferences associated with each FVIII assay.
To identify clinical scenarios where chromogenic FVIII assays may offer superior performance.

Main Methods:

Review of existing literature on FVIII activity assays.
Comparative analysis of one-stage clotting, two-stage clotting, and chromogenic assay principles.
Discussion of factors influencing assay performance, including reagent variability and lupus anticoagulants.

Main Results:

Each FVIII assay presents unique characteristics regarding ease of use, reagent availability, and sensitivity.
Clot-based assays (one-stage and two-stage) can be susceptible to interference from lupus anticoagulants.
Chromogenic assays offer distinct advantages in specific clinical situations, particularly for mild hemophilia A.

Conclusions:

The choice of FVIII assay depends on clinical context, laboratory resources, and potential interferences.
Chromogenic FVIII assays can provide more reliable results in the presence of certain inhibitors.
Understanding assay limitations is essential for accurate hemophilia A diagnosis and patient management.